Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 12/20 | 0.46 |
| ▸ | AKT2 | P31751 | 8/20 | 0.44 |
| ▸ | AKT3 | Q9Y243 | 6/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31455851 | 1.00 | AKT1 (0.46) | AKT1AKT2AKT3MMP9GRM5 | |
| SCHEMBL31455947 | 0.93 | AKT1 (0.44) | AKT1AKT2AKT3MMP9GRM5 | |
| SCHEMBL31455265 | 0.85 | AKT1 (0.45) | AKT1AKT2AKT3 | |
| SCHEMBL31455126 | 0.83 | AKT1 (0.43) | AKT1AKT2AKT3 | |
| SCHEMBL31455477 | 0.79 | AKT1 (0.46) | AKT1AKT2AKT3 | |
| SCHEMBL31455860 | 0.77 | AKT1 (0.47) | AKT1AKT2AKT3 | |
| SCHEMBL31455703 | 0.76 | AKT1 (0.48) | AKT1AKT2AKT3 | |
| SCHEMBL31420329 | 0.75 | AKT1 (0.50) | AKT1AKT2AKT3 | |
| SCHEMBL31455914 | 0.74 | AKT1 (0.48) | AKT1AKT2AKT3 | |
| SCHEMBL31455657 | 0.73 | AKT1 (0.65) | AKT1AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059562-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |